Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free ENVB Stock Alerts

Enveric Biosciences (ENVB) Competitors

Enveric Biosciences logo
$1.33 +0.01 (+0.68%)
As of 01:27 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare

ENVB vs. KZIA, CLRB, AIXC, PLUR, and LPCN

Should you buy Enveric Biosciences stock or one of its competitors? MarketBeat compares Enveric Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Enveric Biosciences include Novogen (KZIA), Cellectar Biosciences (CLRB), Qualigen Therapeutics (AIXC), Pluri (PLUR), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry.

How does Enveric Biosciences compare to Novogen?

Enveric Biosciences (NASDAQ:ENVB) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

13.8% of Enveric Biosciences shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 2.4% of Enveric Biosciences shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Enveric Biosciences has higher earnings, but lower revenue than Novogen.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric BiosciencesN/AN/A-$8.77M-$23.54N/A
Novogen$30K746.35-$13.41MN/AN/A

Novogen has a consensus price target of $25.80, suggesting a potential upside of 90.13%. Given Novogen's stronger consensus rating and higher probable upside, analysts clearly believe Novogen is more favorable than Enveric Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Novogen
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.67

In the previous week, Enveric Biosciences and Enveric Biosciences both had 2 articles in the media. Enveric Biosciences' average media sentiment score of 1.44 beat Novogen's score of 0.67 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Enveric Biosciences Positive
Novogen Positive

Enveric Biosciences has a beta of 1.15, indicating that its stock price is 15% more volatile than the broader market. Comparatively, Novogen has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Novogen's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enveric BiosciencesN/A -220.97% -177.47%
Novogen N/A N/A N/A

Summary

Novogen beats Enveric Biosciences on 8 of the 11 factors compared between the two stocks.

How does Enveric Biosciences compare to Cellectar Biosciences?

Cellectar Biosciences (NASDAQ:CLRB) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, dividends, media sentiment, risk and earnings.

In the previous week, Cellectar Biosciences had 12 more articles in the media than Enveric Biosciences. MarketBeat recorded 14 mentions for Cellectar Biosciences and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.44 beat Cellectar Biosciences' score of 1.22 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Cellectar Biosciences Positive
Enveric Biosciences Positive

Cellectar Biosciences is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cellectar BiosciencesN/AN/A-$21.79M-$6.66N/A
Enveric BiosciencesN/AN/A-$8.77M-$23.54N/A

16.4% of Cellectar Biosciences shares are held by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are held by institutional investors. 2.6% of Cellectar Biosciences shares are held by insiders. Comparatively, 2.4% of Enveric Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Enveric Biosciences' return on equity of -220.97% beat Cellectar Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Cellectar BiosciencesN/A -349.24% -153.18%
Enveric Biosciences N/A -220.97%-177.47%

Cellectar Biosciences has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.15, meaning that its stock price is 15% more volatile than the broader market.

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 318.73%. Given Cellectar Biosciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectar Biosciences is more favorable than Enveric Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectar Biosciences
1 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.80
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Summary

Cellectar Biosciences beats Enveric Biosciences on 9 of the 14 factors compared between the two stocks.

How does Enveric Biosciences compare to Qualigen Therapeutics?

Qualigen Therapeutics (NASDAQ:AIXC) and Enveric Biosciences (NASDAQ:ENVB) are both small-cap pharmaceutical products companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

Enveric Biosciences' return on equity of -220.97% beat Qualigen Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Qualigen TherapeuticsN/A -771.52% -79.52%
Enveric Biosciences N/A -220.97%-177.47%

Qualigen Therapeutics has a beta of 0.49, indicating that its share price is 51% less volatile than the broader market. Comparatively, Enveric Biosciences has a beta of 1.15, indicating that its share price is 15% more volatile than the broader market.

In the previous week, Qualigen Therapeutics had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 3 mentions for Qualigen Therapeutics and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.44 beat Qualigen Therapeutics' score of 0.06 indicating that Enveric Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Qualigen Therapeutics Neutral
Enveric Biosciences Positive

Qualigen Therapeutics is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Qualigen TherapeuticsN/AN/A-$16.97M-$6.47N/A
Enveric BiosciencesN/AN/A-$8.77M-$23.54N/A

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Qualigen Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

3.2% of Qualigen Therapeutics shares are owned by institutional investors. Comparatively, 13.8% of Enveric Biosciences shares are owned by institutional investors. 1.2% of Qualigen Therapeutics shares are owned by company insiders. Comparatively, 2.4% of Enveric Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Enveric Biosciences beats Qualigen Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Enveric Biosciences compare to Pluri?

Enveric Biosciences (NASDAQ:ENVB) and Pluri (NASDAQ:PLUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, media sentiment, dividends, valuation and earnings.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Pluri
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

In the previous week, Pluri had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 3 mentions for Pluri and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.44 beat Pluri's score of 0.62 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Enveric Biosciences Positive
Pluri Positive

Enveric Biosciences has higher earnings, but lower revenue than Pluri. Pluri is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric BiosciencesN/AN/A-$8.77M-$23.54N/A
Pluri$1.34M13.82-$22.58M-$4.53N/A

Enveric Biosciences has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Pluri has a beta of 0.64, meaning that its share price is 36% less volatile than the broader market.

Enveric Biosciences has a net margin of 0.00% compared to Pluri's net margin of -2,162.08%. Pluri's return on equity of 0.00% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enveric BiosciencesN/A -220.97% -177.47%
Pluri -2,162.08%N/A -106.59%

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 16.6% of Pluri shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by insiders. Comparatively, 43.2% of Pluri shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Pluri beats Enveric Biosciences on 7 of the 12 factors compared between the two stocks.

How does Enveric Biosciences compare to Lipocine?

Enveric Biosciences (NASDAQ:ENVB) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations.

In the previous week, Lipocine had 1 more articles in the media than Enveric Biosciences. MarketBeat recorded 3 mentions for Lipocine and 2 mentions for Enveric Biosciences. Enveric Biosciences' average media sentiment score of 1.44 beat Lipocine's score of 0.63 indicating that Enveric Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Enveric Biosciences Positive
Lipocine Positive

Enveric Biosciences has a beta of 1.15, meaning that its share price is 15% more volatile than the broader market. Comparatively, Lipocine has a beta of 0.44, meaning that its share price is 56% less volatile than the broader market.

13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 2.4% of Enveric Biosciences shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Enveric Biosciences has higher earnings, but lower revenue than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Enveric Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Enveric BiosciencesN/AN/A-$8.77M-$23.54N/A
Lipocine$1.98M9.80-$9.63M-$1.88N/A

Enveric Biosciences has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Lipocine's return on equity of -66.70% beat Enveric Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Enveric BiosciencesN/A -220.97% -177.47%
Lipocine -571.18%-66.70%-59.39%

Lipocine has a consensus price target of $15.00, suggesting a potential upside of 536.67%. Given Lipocine's stronger consensus rating and higher probable upside, analysts clearly believe Lipocine is more favorable than Enveric Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enveric Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Lipocine
1 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.33

Summary

Lipocine beats Enveric Biosciences on 9 of the 15 factors compared between the two stocks.

Get Enveric Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ENVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ENVB vs. The Competition

Export
MetricEnveric BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$4.92M$3.66B$6.78B$12.59B
Dividend YieldN/A2.19%2.68%8.43%
P/E Ratio-0.0621.6327.1124.33
Price / SalesN/A326.37525.1092.04
Price / CashN/A143.6648.5959.39
Price / Book0.198.5010.826.30
Net Income-$8.77M$23.88M$3.59B$331.45M
7 Day Performance-6.41%-3.22%-1.53%-0.08%
1 Month Performance-10.20%5.42%2.75%-0.96%
1 Year Performance-91.00%51.50%28.40%19.89%

Enveric Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
ENVB
Enveric Biosciences
1.1018 of 5 stars		$1.33
+0.7%		N/A-91.8%$4.92MN/AN/A20
KZIA
Novogen
1.8543 of 5 stars		$12.82
-2.1%		$25.80
+101.2%		+17.8%$21.12M$30KN/A12
CLRB
Cellectar Biosciences
4.2616 of 5 stars		$2.63
-2.6%		$11.00
+318.1%		-47.2%$21.05MN/AN/A10
AIXC
Qualigen Therapeutics
0.1545 of 5 stars		$1.03
-1.4%		N/AN/A$20.75MN/AN/A50
PLUR
Pluri
0.8267 of 5 stars		$1.91
-7.8%		N/A-66.9%$20.24M$1.34MN/A150

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:ENVB) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran's New Leader Just Said Something That Should Terrify Every American
Iran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...
American Alternative | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel